FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783755582> ?p ?o ?g. }

• W2783755582 endingPage "43" @default.
• W2783755582 startingPage "38" @default.
• W2783755582 abstract "First-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy. Amrubicin is a synthetic anthracycline with single-agent activity in relapsed/refractory SCLC. In an attempt to improve treatment efficacy, we evaluated amrubicin/carboplatin as first-line therapy for extensive-stage SCLC.In this multicenter phase II trial, patients received amrubicin (30 mg/m2 daily on Days 1, 2, and 3) and carboplatin (AUC = 5 on Day 1); cycles were repeated every 21 days for 4 cycles. Pegfilgrastim (6 mg subcutaneously) was administered on Day 4 of all cycles. Overall survival (OS) proportion at 1 year was the primary endpoint. The target 1-year OS rate was 47%, an improvement of 35% from historical results with carboplatin/etoposide.Eighty patients received study treatment, and 62% completed the planned 4 courses. The overall response rate was 74% (13% complete responses). The 1-year survival rate was 38% (95% CI: 25, 50). The median survival was 10 months. Myelosuppression was severe but manageable.The combination of amrubicin/carboplatin was an active first-line treatment for extensive stage SCLC, but showed no indication of increased efficacy compared to standard treatments. Severe myelosuppression was common with this regimen, in spite of prophylactic pegfilgrastim. These results are consistent with those of other trials in showing no role for amrubicin in the first-line treatment of SCLC." @default.
• W2783755582 created "2018-01-26" @default.
• W2783755582 creator A5018054038 @default.
• W2783755582 creator A5041493814 @default.
• W2783755582 creator A5053359739 @default.
• W2783755582 creator A5065865976 @default.
• W2783755582 creator A5065917441 @default.
• W2783755582 creator A5072308451 @default.
• W2783755582 creator A5073724595 @default.
• W2783755582 creator A5079398298 @default.
• W2783755582 creator A5090068456 @default.
• W2783755582 date "2018-03-01" @default.
• W2783755582 modified "2023-09-26" @default.
• W2783755582 title "Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium" @default.
• W2783755582 cites W1971264126 @default.
• W2783755582 cites W2015146231 @default.
• W2783755582 cites W2019607817 @default.
• W2783755582 cites W2089993835 @default.
• W2783755582 cites W2103702213 @default.
• W2783755582 cites W2107842653 @default.
• W2783755582 cites W2115465348 @default.
• W2783755582 cites W2120435735 @default.
• W2783755582 cites W2123767004 @default.
• W2783755582 cites W2133266907 @default.
• W2783755582 cites W2151177054 @default.
• W2783755582 cites W2166418266 @default.
• W2783755582 cites W2170260373 @default.
• W2783755582 cites W2915478882 @default.
• W2783755582 doi "https://doi.org/10.1016/j.lungcan.2018.01.007" @default.
• W2783755582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29496254" @default.
• W2783755582 hasPublicationYear "2018" @default.
• W2783755582 type Work @default.
• W2783755582 sameAs 2783755582 @default.
• W2783755582 citedByCount "3" @default.
• W2783755582 countsByYear W27837555822018 @default.
• W2783755582 countsByYear W27837555822020 @default.
• W2783755582 countsByYear W27837555822021 @default.
• W2783755582 crossrefType "journal-article" @default.
• W2783755582 hasAuthorship W2783755582A5018054038 @default.
• W2783755582 hasAuthorship W2783755582A5041493814 @default.
• W2783755582 hasAuthorship W2783755582A5053359739 @default.
• W2783755582 hasAuthorship W2783755582A5065865976 @default.
• W2783755582 hasAuthorship W2783755582A5065917441 @default.
• W2783755582 hasAuthorship W2783755582A5072308451 @default.
• W2783755582 hasAuthorship W2783755582A5073724595 @default.
• W2783755582 hasAuthorship W2783755582A5079398298 @default.
• W2783755582 hasAuthorship W2783755582A5090068456 @default.
• W2783755582 hasConcept C121608353 @default.
• W2783755582 hasConcept C126322002 @default.
• W2783755582 hasConcept C141071460 @default.
• W2783755582 hasConcept C143998085 @default.
• W2783755582 hasConcept C203092338 @default.
• W2783755582 hasConcept C2776256026 @default.
• W2783755582 hasConcept C2776694085 @default.
• W2783755582 hasConcept C2776802502 @default.
• W2783755582 hasConcept C2777063308 @default.
• W2783755582 hasConcept C2778119113 @default.
• W2783755582 hasConcept C2778239845 @default.
• W2783755582 hasConcept C2778658803 @default.
• W2783755582 hasConcept C2778850193 @default.
• W2783755582 hasConcept C2781413609 @default.
• W2783755582 hasConcept C2781451048 @default.
• W2783755582 hasConcept C31760486 @default.
• W2783755582 hasConcept C530470458 @default.
• W2783755582 hasConcept C535046627 @default.
• W2783755582 hasConcept C71924100 @default.
• W2783755582 hasConceptScore W2783755582C121608353 @default.
• W2783755582 hasConceptScore W2783755582C126322002 @default.
• W2783755582 hasConceptScore W2783755582C141071460 @default.
• W2783755582 hasConceptScore W2783755582C143998085 @default.
• W2783755582 hasConceptScore W2783755582C203092338 @default.
• W2783755582 hasConceptScore W2783755582C2776256026 @default.
• W2783755582 hasConceptScore W2783755582C2776694085 @default.
• W2783755582 hasConceptScore W2783755582C2776802502 @default.
• W2783755582 hasConceptScore W2783755582C2777063308 @default.
• W2783755582 hasConceptScore W2783755582C2778119113 @default.
• W2783755582 hasConceptScore W2783755582C2778239845 @default.
• W2783755582 hasConceptScore W2783755582C2778658803 @default.
• W2783755582 hasConceptScore W2783755582C2778850193 @default.
• W2783755582 hasConceptScore W2783755582C2781413609 @default.
• W2783755582 hasConceptScore W2783755582C2781451048 @default.
• W2783755582 hasConceptScore W2783755582C31760486 @default.
• W2783755582 hasConceptScore W2783755582C530470458 @default.
• W2783755582 hasConceptScore W2783755582C535046627 @default.
• W2783755582 hasConceptScore W2783755582C71924100 @default.
• W2783755582 hasLocation W27837555821 @default.
• W2783755582 hasLocation W27837555822 @default.
• W2783755582 hasOpenAccess W2783755582 @default.
• W2783755582 hasPrimaryLocation W27837555821 @default.
• W2783755582 hasRelatedWork W1847381023 @default.
• W2783755582 hasRelatedWork W1988489713 @default.
• W2783755582 hasRelatedWork W1989051367 @default.
• W2783755582 hasRelatedWork W2002016229 @default.
• W2783755582 hasRelatedWork W2396161326 @default.
• W2783755582 hasRelatedWork W2403217642 @default.
• W2783755582 hasRelatedWork W2417735298 @default.
• W2783755582 hasRelatedWork W3148051207 @default.
• W2783755582 hasRelatedWork W4253012358 @default.

• next